Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
Public ClinicalTrials.gov record NCT03667690. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).
Study identification
- NCT ID
- NCT03667690
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 199 participants
Conditions and interventions
Conditions
Interventions
- Rezafungin for Injection Drug
- Caspofungin Drug
- Fluconazole Drug
- intravenous placebo Drug
- oral placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2018 (Actual)
- Primary completion
- Oct 7, 2021 (Actual)
- Completion
- Oct 7, 2021 (Actual)
- Last update posted
- Jan 6, 2023
2018 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | — |
| UC Davis | Sacramento | California | 95817 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Johns Hopkins | Baltimore | Maryland | 21287 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Mayo Clinic Hospital-Rochester | Rochester | Minnesota | 55902 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Washington University St. Louis | St Louis | Missouri | 63110 | — |
| Mecury Street Medical | Butte | Montana | 59701 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| ID Clinical Research, Ltd. | Toledo | Ohio | 43608 | — |
| University of Pittsburgh Falk Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Reading Hospital and Medical Center | West Reading | Pennsylvania | 19611 | — |
| The University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | — |
| Baylor Scott and White Medical Center | Temple | Texas | 76508 | — |
| Carilion Clinic | Roanoke | Virginia | 24014 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 113 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03667690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2023 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03667690 live on ClinicalTrials.gov.